This study is designed to improve knowledge regarding the initial effectiveness of N-acetylcysteine (NAC) on cold and cough symptoms.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
70
Unnamed facility
Chicoutimi, Quebec, Canada
Unnamed facility
Montreal, Quebec, Canada
Unnamed facility
Québec, Quebec, Canada
Unnamed facility
Sherbrook, Quebec, Canada
Unnamed facility
Victoriaville, Quebec, Canada
Cough Count (Number of Coughs Will be Measured by a 24-hour Ambulatory Cough Monitoring System for the First 72 Hours)
Number of coughs will be measured by a 24-hour ambulatory cough monitoring system for the first 72 hours
Time frame: 72 hours
Safety of Daily Dose of NAC (Number of Patients With Adverse Advents)
Number of patients with adverse advents
Time frame: 7 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.